Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line
Open Access
- 4 March 2011
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 54 (6) , 1567-1578
Abstract
Aims/hypothesis Recent studies have demonstrated that cannabinoid-1 (CB1) receptor blockade ameliorated inflammation, endothelial and/or cardiac dysfunction, and cell death in models of nephropathy, atherosclerosis and cardiomyopathy. However the role of CB1 receptor signalling in diabetic retinopathy remains unexplored. Using genetic deletion or pharmacological inhibition of the CB1 receptor with SR141716 (rimonabant) in a rodent model of diabetic retinopathy or in human primary retinal endothelial cells (HREC) exposed to high glucose, we explored the role of CB1 receptors in the pathogenesis of diabetic retinopathy. Methods Diabetes was induced using streptozotocin in C57BL/6J Cb 1 (also known as Cnr1)+/+ and Cb 1 −/− mice aged 8 to 12 weeks. Samples from mice retina or HREC were used to determine: (1) apoptosis; (2) activity of nuclear factor kappa B, intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), poly (ADP-ribose) polymerase and caspase-3; (3) content of 3-nitrotyrosine and reactive oxygen species; and (4) activation of p38/Jun N-terminal kinase/mitogen-activated protein kinase (MAPK). Results Deletion of CB1 receptor or treatment of diabetic mice with CB1 receptor antagonist SR141716 prevented retinal cell death. Treatment of diabetic mice or HREC cells exposed to high glucose with SR141716 attenuated the oxidative and nitrative stress, and reduced levels of nuclear factor κB, ICAM-1 and VCAM-1. In addition, SR141716 attenuated the diabetes- or high glucose-induced pro-apoptotic activation of MAPK and retinal vascular cell death. Conclusions/interpretation Activation of CB1 receptors may play an important role in the pathogenesis of diabetic retinopathy by facilitating MAPK activation, oxidative stress and inflammatory signalling. Conversely, CB1 receptor inhibition may be beneficial in the treatment of this devastating complication of diabetes.Keywords
This publication has 50 references indexed in Scilit:
- Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injuryFree Radical Biology and Medicine, 2011
- Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic CardiomyopathyJACC, 2010
- CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy modelBritish Journal of Pharmacology, 2010
- Cannabinoid‐1 receptor activation induces reactive oxygen species‐dependent and ‐independent mitogen‐activated protein kinase activation and cell death in human coronary artery endothelial cellsBritish Journal of Pharmacology, 2010
- CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytesCardiovascular Research, 2009
- Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and StrokeJournal of Neuroimmune Pharmacology, 2009
- The cannabinoid receptor‐1 antagonist rimonabant inhibits platelet activation and reduces pro‐inflammatory chemokines and leukocytes in Zucker ratsBritish Journal of Pharmacology, 2008
- Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioningBritish Journal of Pharmacology, 2008
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJACC, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006